Evolent Health announced Q2 2026 results showing revenue of $652.5 million, up from $444.3 million in Q2 2025, with a reduced net loss of $28.4 million. The company raised its full-year 2026 revenue guidance to $2.6-$2.7 billion and expects over 25% revenue growth in 2027, driven by new partnerships and demand for oncology solutions. Despite industry challenges, Evolent projects adjusted EBITDA between $120-$135 million for 2026 and aims to improve cash flow and reduce debt. Upcoming launches include a major Oncology Performance Suite covering 1.5 million lives across 11 states, expected to generate $300 million annually starting December 2026.
NexGold Mining is currently valued at a very low 0.13x price-to-net asset value (P/NAV) despite owning the fully permitted, high-grade Goldboro project. Key upcoming catalysts include the updated Goldboro Feasibility Study expected by year-end, a con...
Zakura has released an open-source library called Zakura Common that reduces Zcash shielded transaction times from over three seconds to under 200 milliseconds without requiring network changes or a hard fork. This upgrade significantly improves mobi...
Cronos validators stopped block production on August 30 following a $75 million exploit in Tectonic, a decentralized lending protocol on its blockchain. The attack involved inflating the price of Tectonic's governance token, TONIC, to borrow assets f...
HDFC Bank's CEO Sashidhar Jagdishan announced he will not seek reappointment after his term ends in October, causing shares to initially rise 2.5%. The bank's stock has fallen 27% this year amid leadership uncertainty and governance concerns. Analyst...
Mantle (MNT) surged 10.34% to $0.57 amid a broad mid-cap rally, but on-chain data shows most volume is wash trading and exchange inflows suggest selling pressure. No clear catalyst was identified, though some ecosystem activity was noted. Key levels ...
